TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT02733133: A Single-Dose, Single Period, Phase II Pharmacokinetic Study To Examine Testagen™ TDS®-Testosterone For Its Potential To Be Inadvertently Transferred By Skin Contact After Dosing In Healthy Adult Subjects

Sponsor: Transdermal Delivery Solutions Corp · Phase: PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 96 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,256,000

Rescue Site Savings

+$5,443,800

Unlock Full NCT02733133 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT02733133 Rescue Dossier →